Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10023313rdf:typepubmed:Citationlld:pubmed
pubmed-article:10023313lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0034380lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C1516985lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0228174lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:10023313lifeskim:mentionsumls-concept:C0282461lld:lifeskim
pubmed-article:10023313pubmed:issue12lld:pubmed
pubmed-article:10023313pubmed:dateCreated1999-2-25lld:pubmed
pubmed-article:10023313pubmed:abstractTextIn 1985, the EORTC Radiotherapy Co-operative Group launched a randomised phase III study comparing high-dose (59.4 Gy in 6.5 weeks) versus low-dose (45 Gy in 5 weeks) radiotherapy with conventional techniques in patients diagnosed with low-grade cerebral glioma. The primary endpoint of the study was survival. No difference in survival was observed between the two treatment strategies. A quality of life (QoL) questionnaire consisting of 47 items assessing a range of physical, psychological, social, and symptom domains was included in the trial to measure the impact of treatment over time. Patients who received high-dose radiotherapy tended to report lower levels of functioning and more symptom burden following completion of radiotherapy. These group differences were statistically significant for fatigue/malaise and insomnia immediately after radiotherapy and in leisure time and emotional functioning at 7-15 months after randomisation. These findings suggest that for conventional radiotherapy for low-grade cerebral glioma, a schedule of 45 Gy in 5 weeks not only saves valuable resources, but also spares patients a prolonged treatment at no loss of clinical efficacy.lld:pubmed
pubmed-article:10023313pubmed:languageenglld:pubmed
pubmed-article:10023313pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10023313pubmed:citationSubsetIMlld:pubmed
pubmed-article:10023313pubmed:statusMEDLINElld:pubmed
pubmed-article:10023313pubmed:monthNovlld:pubmed
pubmed-article:10023313pubmed:issn0959-8049lld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:NordmanEElld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:KarimA BABlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:BolleAAlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:AaronsonN KNKlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:RuttenE HEHlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:PierartMMlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:KiebertG MGMlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:SilvestreM...lld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:CurranDDlld:pubmed
pubmed-article:10023313pubmed:authorpubmed-author:MentenJJlld:pubmed
pubmed-article:10023313pubmed:issnTypePrintlld:pubmed
pubmed-article:10023313pubmed:volume34lld:pubmed
pubmed-article:10023313pubmed:ownerNLMlld:pubmed
pubmed-article:10023313pubmed:authorsCompleteYlld:pubmed
pubmed-article:10023313pubmed:pagination1902-9lld:pubmed
pubmed-article:10023313pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:meshHeadingpubmed-meshheading:10023313...lld:pubmed
pubmed-article:10023313pubmed:year1998lld:pubmed
pubmed-article:10023313pubmed:articleTitleQuality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.lld:pubmed
pubmed-article:10023313pubmed:affiliationMEDTAP International, London, U.K.lld:pubmed
pubmed-article:10023313pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10023313pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10023313pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10023313pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10023313lld:pubmed